Vensun Pharmaceuticals
A U.S.-based pharmaceutical company focused on development, regulatory filing, and commercialization of generic prescription products. The company collaborates with strategic manufacturing partners, maintains ANDA filings with the FDA, and manages distribution and commercial operations for a portfolio of generic medicines.
Industries
Nr. of Employees
small (1-50)
Vensun Pharmaceuticals
Products
Amantadine hydrochloride (capsules and tablets), 100 mg
Generic formulations of amantadine hydrochloride in oral dosage forms for prescription use.
Carisoprodol tablets (250 mg, 350 mg)
Generic carisoprodol oral tablets. Noted as one of the company's launched products.
Clopidogrel tablets (75 mg)
Generic clopidogrel oral tablets for antiplatelet therapy.
Donepezil hydrochloride tablets (5 mg, 10 mg)
Generic donepezil oral tablets for prescription use.
Fluoxetine capsules (10 mg, 20 mg, 40 mg)
Generic fluoxetine oral capsules in multiple strengths.
Hydrocortisone tablets (5 mg, 10 mg, 20 mg)
Generic hydrocortisone oral tablets in multiple strengths.
Amantadine hydrochloride (capsules and tablets), 100 mg
Generic formulations of amantadine hydrochloride in oral dosage forms for prescription use.
Carisoprodol tablets (250 mg, 350 mg)
Generic carisoprodol oral tablets. Noted as one of the company's launched products.
Clopidogrel tablets (75 mg)
Generic clopidogrel oral tablets for antiplatelet therapy.
Donepezil hydrochloride tablets (5 mg, 10 mg)
Generic donepezil oral tablets for prescription use.
Fluoxetine capsules (10 mg, 20 mg, 40 mg)
Generic fluoxetine oral capsules in multiple strengths.
Hydrocortisone tablets (5 mg, 10 mg, 20 mg)
Generic hydrocortisone oral tablets in multiple strengths.
Services
End-to-end development of generic prescription products and preparation of ANDA submissions for FDA review.
Management of manufacturing, supply and distribution agreements with third-party manufacturers to enable commercialization.
Regulatory strategy, submissions and compliance oversight to obtain and maintain approvals for generic products.
Sales, marketing and distribution management for approved generic products and exclusive distribution rights.
End-to-end development of generic prescription products and preparation of ANDA submissions for FDA review.
Management of manufacturing, supply and distribution agreements with third-party manufacturers to enable commercialization.
Regulatory strategy, submissions and compliance oversight to obtain and maintain approvals for generic products.
Sales, marketing and distribution management for approved generic products and exclusive distribution rights.
Expertise Areas
- Generic drug development
- ANDA regulatory submissions and management
- Formulation and analytical development
- Contract manufacturing and supply agreements
Key Technologies
- Formulation development
- Analytical method development
- Pharmacokinetic analysis
- Regulatory submissions (ANDA)
News & Updates
Completed a $22.5 million Series C financing round led by an investment firm.
Announcement of the launch of an ANDA-approved carisoprodol tablet product from the company's development portfolio.
Entered a manufacturing, supply and distribution agreement to commercialize a multi-product portfolio (agreement referenced to commercialize 23 products).
Completed a $15.8 million Series B financing round.
Raised $5.7 million in Series A financing and established as a Delaware C corporation.
Completed a $22.5 million Series C financing round led by an investment firm.
Announcement of the launch of an ANDA-approved carisoprodol tablet product from the company's development portfolio.
Entered a manufacturing, supply and distribution agreement to commercialize a multi-product portfolio (agreement referenced to commercialize 23 products).
Completed a $15.8 million Series B financing round.
Raised $5.7 million in Series A financing and established as a Delaware C corporation.